NEW YORK, June 4, 2021 /PRNewswire/ -- AIkido Pharma Inc.
(Nasdaq: AIKI) ("AIkido" or the "Company") today announced that
positive Phase 1 testing data was presented at the 2021 ASCO Annual
Meeting June 4, 2021. The
poster presentation of the data was by Dr. Scott Tagawa, a Professor of Medicine &
Urology at Weill Cornell Medicine and an AIkido Pharma Scientific
Advisory Board member. The full presentation is available
at: https://conferences.asco.org
Highlights from the presentation include:
- Declining PSA levels in treated patients
- Declining circulating tumor cell (CTC) count in treated
patients
- Actinium-225 radiolabeled J591 well-tolerated with preliminary
evidence of efficacy in a heavily pre-treated patient
population
- Actinium-225 radiolabeled J591 safe at tested dosage
- Phase 2 trial underway
Neal Shore, MD, FACS a well-known
key opinion leader in prostate cancer research, Medical Director
for the Carolina Urologic Research Center and recent addition to
the Company's Advisory Board, stated, "The Phase I trial results of
the 225Ac-J591 antibody for these advanced prostate cancer
patients, who had extensive tumor burden as well as having
experienced numerous life prolonging therapies, are impressive,
both from a response and safety standpoint. PSA declines and CTC
responses were clearly evident. Additionally, this novel antibody
conjugate demonstrated very good tolerability during this DLT phase
1 trial. The unique properties of 225Ac-J591 suggest it as a very
promising candidate for combination treatment with beta emitters,
whereby the synergy of therapeutic isotope combination and broader
tumor effect would have the potential to further shape theragnostic
platforms."
Full ASCO Presentation Details:
Title: "Phase I study of 225Ac-J591 for men with
metastatic castration-resistant prostate cancer (mCRPC)"
Tract: Genitourinary Cancer—Prostate, Testicular,
and Penile
Presenter: Dr. Scott
Tagawa MD, MS, FACP
Abstract Number: 5015
Date and Time: Available Starting June 4, 2021, 9:00 am
(EST)
The Abstract from this study has been released on the ASCO
Annual Meeting website (https://conferences.asco.org). Clinical
trial
information: NCT03276572 (https://meetinglibrary.asco.org/record/196409/abstract
)
The full ASCO meeting program is available at: www.asco.org
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a
biotechnology Company with a diverse portfolio of small-molecule
anti-cancer therapeutics. The Company's platform consists of
patented technology from leading universities and researchers, and
we are currently in the process of developing an innovative
therapeutic drug platform through strong partnerships with world
renowned educational institutions, including The University of
Texas at
Austin and University of Maryland at Baltimore. Our diverse pipeline of
therapeutics includes therapies for pancreatic cancer and prostate
cancer. We are constantly seeking to grow our pipeline to treat
unmet medical needs in oncology. The Company is also
developing a broad-spectrum antiviral platform that may potentially
inhibit replication of multiple viruses including Influenza virus,
SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its business contained therein. Thus, actual
results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido Pharma Inc.:
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-announces-positive-phase-1-data-presented-at-asco-on-225ac-j591-301306027.html
SOURCE AIkido Pharma Inc.